Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

The Impact of Adjuvant Androgen Deprivation Following Radical Prostatectomy on Prostate Cancer Recurrence

Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.

Study Overview

• Status: Recruiting
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Lupron Depot

• Study Type: Interventional
• Enrollment (Estimated): 72
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Rodney Breau, Dr.; Phone Number: 73019 613-737-8899; Email: rbreau@toh.on.ca

Study Locations

• Canada
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 2Y9
      • Recruiting
      • Nova Scotia Health
      • Contact: Ricardo Rendon, MD; Phone Number: 902-425-3940; Email: Ricardo.Rendon@nshealth.ca
      • Principal Investigator: Ricardo Rendon, Dr.
  • Ontario
    • Ottawa, Ontario, Canada, K1H 8L6
      • Recruiting
      • The Ottawa Hospital
      • Contact: Rodney H Breau, MD, FRCSC; Phone Number: 73019 613-737-8899; Email: rbreau@ottawahospital.on.ca
      • Contact: Pascale Juneau, MASc; Phone Number: 73852 613-737-8899; Email: pjuneau@ohri.ca
      • Principal Investigator: Rodney H Breau, MD
  • Quebec
    • Montreal, Quebec, Canada, H4A 3J1
      • Not yet recruiting
      • Centre universitaire de santé McGill - McGill University Health Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. undetectable PSA (<0.02 ng/ml) within 16 weeks post-operative;
2. ≥25% predicted risk of PSA recurrence within 5 years of surgery (based on the Kattan nomogram)

Exclusion Criteria:

1. Unwilling to receive ADT;
2. previously received ADT;
3. lymph node metastases
4. allergy to any form of ADT

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Standard of Care
Experimental: Standard of Care plus Androgen Deprivation Therapy (Lupron Depot); 22.5 mg intra-muscular injection of Lupron Depot every 3 months for 12 months (4 injections total)	Drug: Lupron Depot; Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of enrolment	Rate (patients/month) of enrolment	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of enrolment per site	Rate (patients/month) of enrolment per site	1 year
Proportion of patients completing study intervention per-protocol	Proportion of patients completing study intervention per-protocol	1 year
Time to study start-up	Time to study start-up at each site	1 year
Completeness of study assessments	Proportion of study assessments completed per-protocol	1 year

Collaborators and Investigators

• Sponsor: Ottawa Hospital Research Institute
• Collaborators: Tolmar Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): March 6, 2023
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2028

Study Registration Dates

• First Submitted: March 1, 2021
• First Submitted That Met QC Criteria: December 22, 2021
• First Posted (Actual): December 23, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 17, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Pathologic Processes; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Prostatic Diseases; Male Urogenital Diseases; Disease Attributes; Prostatic Neoplasms; Recurrence; Antineoplastic Agents; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Reproductive Control Agents; Fertility Agents, Female; Fertility Agents; Leuprolide
• Other Study ID Numbers: Adjuvant ADT Pilot

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: N/A. IPD not planned to be shared

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No